Saturday, August 2, 2025 8/2/2025

BMT Survivor Study-2 (BMTSS-2)

Award Number: U01CA213140
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2019
PERIOD OF PERFORMANCE END DATE: 03/31/2025

Group Awards By:

View Award Description

BMT Survivor Study-2 (BMTSS-2) - In 2017, an estimated 1.3 million individuals were living with a hematologic malignancy (HM: leukemia, myeloma or lymphoma) in the US. Frontline use of systemic high-intensity chemotherapy with or without radiation characterizes the management of HM. Patients with progressive disease or at high risk of relapse are treated with even higher intensity chemotherapy/radiation and blood or marrow transplantation (BMT); indeed, BMT is often the only curative option for these patients. Steady improvements in outcome have resulted in a growing number of BMT-HM survivors – a population that is uniquely vulnerable to long-term chronic health conditions (CHCs) that are directly related to the high-intensity therapeutic exposures (e.g., subsequent neoplasms, heart failure). In 2000, we constructed a retrospective cohort of 2,333 BMT recipients (City of Hope [COH] or University of Minnesota [UMN]; BMT: 1974-1998), who had survived ≥2y (BMT Survivor Study [BMTSS]; R01 CA78938, Bhatia). While BMTSS has successfully described the high burden of morbidity, accelerated aging and premature mortality in BMT-HM patients, the modest sample size (n=2,333) and the older transplant era (1974-1998) has limited the potential for new discoveries, especially in the face of evolving treatment strategies. We propose a significant enhancement of the existing BMTSS cohort to now include 10,042 HM patients treated with BMT between 1974 and 2014 at COH, UMN or UAB (BMT-HM), as well as a frequency-matched cohort of 3000 HM patients treated with conventional therapy without BMT (non-BMT-HM). This enhanced infrastructure (BMTSS- 2) will be poised to determine the burden of morbidity borne by HM patients treated with or without BMT within the context of individual HM diagnoses, and to understand the pathogenesis of treatment-related health conditions in the setting of accelerated aging. The enhanced BMTSS-2 infrastructure will enable us to: i) understand the long-term risk of health conditions experienced by HM patients treated with and without BMT; ii) determine the association between treatment exposures and health conditions; iii) determine trends in health conditions with changes in treatment strategies; iv) identify interactions between preventable modifiers (comorbidities, health behaviors) and treatment exposures when determining risk of health conditions; v) study the pathogenesis of treatment-related health conditions in the setting of accelerated aging, using genetic markers for susceptibility and epigenetic markers for the association of the health conditions with aging; vi) use HIPAA- compliant technology platform compatible with iOS/Android/iPad/Web-based applications to educate HM patients and measure health behaviors in real time. This is the largest and most comprehensive attempt at examining the health and wellbeing of HM patients treated with and without BMT. The overarching goal is to use BMTSS-2 for translational research along two tracks: A) develop risk prediction models to identify HM recipients at highest risk of treatment-related health conditions; and B) among those identified to be at highest risk, design and test targeted interventions to prevent/ ameliorate these debilitating chronic health conditions.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2023	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH STREET	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cancer Cause and Prevention Research	000	5	5/3/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $1,266,852 )
2023	2023	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cancer Cause and Prevention Research	000	5	6/15/2023	NON-COMPETING CONTINUATION	$1,266,852
														Subtotal = $1,266,852

Issue Date FY: 2022 ( Subtotal = $1,254,755 )
2022	2022	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cancer Cause and Prevention Research	001	4	5/24/2022	NON-COMPETING CONTINUATION	$103,213
2022	2022	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cancer Cause and Prevention Research	000	4	3/11/2022	NON-COMPETING CONTINUATION	$1,151,542
														Subtotal = $1,254,755

Issue Date FY: 2021 ( Subtotal = $1,290,138 )
2021	2021	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cancer Cause and Prevention Research	000	3	3/15/2021	NON-COMPETING CONTINUATION	$1,290,138
														Subtotal = $1,290,138

Issue Date FY: 2020 ( Subtotal = $1,718,115 )
2020	2020	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cancer Cause and Prevention Research	000	2	3/16/2020	NON-COMPETING CONTINUATION	$1,208,716
2020	2020	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cancer Cause and Prevention Research	002	2	8/10/2020	NON-COMPETING CONTINUATION	$150,000
2020	2020	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cancer Cause and Prevention Research	001	2	6/5/2020	NON-COMPETING CONTINUATION	$146,223
2020	2020	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cancer Cause and Prevention Research	004	2	9/22/2020	NON-COMPETING CONTINUATION	$64,676
2020	2020	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cancer Cause and Prevention Research	003	2	8/26/2020	SUPPLEMENT FOR EXPANSION	$148,500
														Subtotal = $1,718,115

Issue Date FY: 2019 ( Subtotal = $1,312,128 )
2019	2019	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cancer Cause and Prevention Research	000	1	4/1/2019	NEW	$1,312,128
														Subtotal = $1,312,128

Grand Total All Awards = $6,841,988

Top

All Categories

About

Search

Reports

Data Submission

Award Information

BMT Survivor Study-2 (BMTSS-2)

Award Number: U01CA213140

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2019

PERIOD OF PERFORMANCE END DATE: 03/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer